Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(36):5884-5897.
doi: 10.2174/0109298673268775231003111540.

Bacterial Polyhydroxyalkanoates-based Therapeutics-delivery Nano-systems

Esteban F Durán-Lara  1   2 , Diana Rafael  3   4 , Fernanda Andrade  3   4 , Olga Lobos G  1 , Sekar Vijayakumar  5
Affiliations
Review

Bacterial Polyhydroxyalkanoates-based Therapeutics-delivery Nano-systems

Esteban F Durán-Lara et al. Curr Med Chem. 2024.

Abstract

Microbial polyhydroxyalkanoates (PHAs) are bio-based aliphatic biopolyester produced by bacteria as an intracellular storage material of carbon and energy under stressed conditions. PHAs have been paid attention to due to their unique and impressive biological properties including high biodegradability, biocompatibility, low cytotoxicity, and different mechanical properties. Under this context, the development of drug-delivery nanosystems based on PHAs has been revealed to have numerous advantages compared with synthetic polymers that included biocompatibility, biodegradability, non-toxic, and low-cost production, among others. In this review article, we present the available state of the art of PHAs. Moreover, we discussed the potential benefits, weaknesses, and perspectives of PHAs to the develop drug delivery systems.

Keywords: Bacterial biopolymers; advanced materials; biomaterials; drug delivery system; film.; nanoparticles; polyhydroxyalkanoate.

PubMed Disclaimer

References

    1. Coelho J.F.; Ferreira P.C.; Alves P.; Cordeiro R.; Fonseca A.C.; Góis J.R.; Gil M.H.; Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. EPMA J 2010,1(1),164-209 - DOI - PubMed
    1. Patra J.K.; Das G.; Fraceto L.F.; Campos E.V.R.; Rodriguez-Torres M.P.; Acosta-Torres L.S.; Diaz-Torres L.A.; Grillo R.; Swamy M.K.; Sharma S.; Habtemariam S.; Shin H.S.; Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018,16(1),71 - DOI - PubMed
    1. Adepu S.; Ramakrishna S.; Controlled drug delivery systems: Current status and future directions. Molecules 2021,26(19),5905 - DOI - PubMed
    1. Majumder J.; Taratula O.; Minko T.; Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliv Rev 2019,144,57-77 - DOI - PubMed
    1. Kenchegowda M.; Rahamathulla M.; Hani U.; Begum M.Y.; Guruswamy S.; Osmani R.A.M.; Gowrav M.P.; Alshehri S.; Ghoneim M.M.; Alshlowi A.; Gowda D.V.; Smart nanocarriers as an emerging platform for cancer therapy: A review. Molecules 2021,27(1),146 - DOI - PubMed

LinkOut - more resources